Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis

79.5/100
Buy Not Halal Healthcare
Price $29.82
Market Cap $6.17B
52-Week Change +28.41%

Is SUPN a good investment?

Supernus Pharmaceuticals, Inc. (SUPN) has a Plutrex AI rating of 79.5/100 as of November 06, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: Best-in-class profitability: Gross margin 85.1% (+54% vs. industry), operating margin 54.8% (+135% vs. industry), net margin 32.8% (+1,390% vs. industry) — SUPN's standalone business generates exceptional cash economics with significant pricing power in CNS specialty pharma. Main concern: Merger completion changes the investment: SUPN shares now convert to 1.5401 Indivior shares — buyers of SUPN at current prices are effectively buying INDV exposure with integration risk, not standalone SUPN fundamentals; the risk/reward calculus shifts to Indivior's ability to execute on the combined CNS platform.

Investment Summary

SUPN presents one of the most compelling deep-value setups in specialty pharma — but the investment thesis has fundamentally changed due to a completed merger with Indivior. Shareholders receive 1.5401 Indivior shares per SUPN share, meaning the standalone SUPN story is effectively closed. For investors not yet holding SUPN, this is now a merger arbitrage play rather than a fundamental equity investment. For the record on standalone fundamentals: P/E of 7.4x (vs. industry 35.7x — a 79% discount), PEG of 0.32 (vs. industry 9.44 — a 97% discount), gross margin of 85.1% (vs. industry 55.3%), operating margin of 54.8% (vs. industry 23.3%), near-zero debt (D/E: 0.03 vs. industry 0.70), and $305M cash. The Headline 'Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical' is the dominant news event — it overrides the standalone fundamental thesis entirely. Headline 'Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates' is a mild positive confirming operational health into the close. Headline 'Supernus Pharmaceuticals Q3 Earnings Call Highlights' and 'Supernus Announces Third Quarter 2026 Financial Results' (EPS $0.93 vs. prior $1.01, -8% YoY) are mildly negative, confirming the near-term earnings softness flagged in fundamentals. The combined entity creates a broader CNS platform, which is strategically sound but introduces integration risk and dependency on Indivior's pipeline.

Key Strengths

Key Concerns

Plutrex 10-Factor AI Breakdown

Financial Health
90/100
Growth Potential
62/100
Valuation
88/100
Profitability
93/100
Debt Management
95/100
Analyst Sentiment
72/100
Technical Momentum
55/100
Insider Confidence
60/100
News Sentiment
68/100

Fundamental Analysis

Standalone SUPN financials are exceptional: Gross margin 85.1% (industry avg 55.3% — 54% premium), operating margin 54.8% (industry avg 23.3% — 135% premium), net margin 32.8% (industry avg 2.2% — 1,390% premium). P/E of 7.4x vs. industry 35.7x represents an extreme 79% discount, while PEG of 0.32 vs. industry 9.44 signals profound undervaluation relative to 5-year EPS CAGR of 23.2%. Balance sheet is fortress-grade: D/E of 0.03 (vs. industry 0.70), $305M cash, positive FCF of $31M. Key concern: near-term EPS growth of only 6.7% (vs. industry 40.1% — 83% laggard), and EPS declined 8% YoY ($1.01 → $0.93 in Q3). ROE of -4.2% (vs. industry 3.1%) reflects accumulated deficit, not operational weakness. Revenue growth of 13.4% is 323% above the industry average of 3.2%. The 5-year EPS CAGR of 23.2% is 94% above the industry average of 12.0%, suggesting the near-term trough is temporary. However, all of this is now secondary — the merger with Indivior (1.5401 Indivior shares per SUPN) means SUPN is effectively a stub security converting to INDV exposure.

News Sentiment

In a transformative deal for the neuroscience pharmaceutical space, Supernus Pharmaceuticals has officially completed its merger with Indivior, creating a diversified CNS biopharmaceutical powerhouse. The headline 'Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical' marks the end of SUPN as an independent stock — shareholders now receive 1.5401 Indivior shares for every SUPN share they hold. The strategic logic is compelling: Indivior, best known for its addiction treatment drug Sublocade, was dangerously dependent on a single product. By absorbing Supernus's broad neurology portfolio — spanning epilepsy, ADHD, and movement disorders — the combined company now has multiple revenue legs to stand on. But the merger arrives at a complicated moment for Supernus's finances. According to 'Supernus Announces Third Quarter 2026 Financial Results,' the company earned $0.93 per share, down from $1.01 a year ago — an 8% drop that underscores the near-term earnings softness that has weighed on SUPN stock all year. The silver lining? As highlighted by 'Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates,' even that lower number topped Wall Street's expectations, suggesting the business remains operationally sound. For everyday investors, the bottom line is simple: SUPN as you knew it no longer exists as a standalone story. What you're really buying now is a bet on whether the new Indivior can successfully blend two very different pharmaceutical cultures into one profitable whole.

Risk Assessment

PRIMARY RISK: The merger completion transforms SUPN into a merger arbitrage/stub situation. Investors buying SUPN now are effectively buying Indivior (INDV) at a fixed exchange ratio of 1.5401x. Key risks include: (1) Indivior share price volatility before settlement, which directly impacts effective SUPN value; (2) Integration execution risk — combining SUPN's neurology portfolio with Indivior's addiction-focused Sublocade franchise creates overlap/complexity; (3) Near-term EPS headwinds at the combined company given SUPN's 6.7% forward growth vs. peers at 40%+; (4) If Indivior shares decline post-merger, SUPN holders bear that exposure. MITIGATION: SUPN's fortress balance sheet ($305M cash, D/E 0.03) provides significant financial cushion entering the merger, reducing integration financial stress. The strategic rationale is sound — diversifying Indivior away from Sublocade concentration into SUPN's broader CNS portfolio reduces single-product risk. For existing SUPN holders: HOLD through the exchange. For new buyers: this is a merger arb play with modest spread if any, not a standalone fundamental investment — position size accordingly at 2% or less.

Related Halal Stocks

Related Stocks

Frequently Asked Questions

Is SUPN a halal stock?

No, Supernus Pharmaceuticals, Inc. (SUPN) is currently not classified as halal by AAOIFI criteria.

What is Plutrex's AI rating for SUPN?

Supernus Pharmaceuticals, Inc. (SUPN) has a Plutrex AI rating of 79.5/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.

Is SUPN a good investment?

According to Plutrex AI, SUPN has a Buy rating (79.5/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.

How can I invest in SUPN?

US stocks like SUPN can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.

What are the main risks of investing in SUPN?

Plutrex AI identifies the main risks for SUPN by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.

Chat with ElBarake AI about SUPN

Ask anything about this stock and get an instant AI-powered answer — free, no signup required.

Open SUPN in ElBarake